- Acne
- Actinic Keratosis
- Aesthetics
- Alopecia
- Atopic Dermatitis
- Buy-and-Bill
- COVID-19
- Case-Based Roundtable
- Chronic Hand Eczema
- Drug Watch
- Eczema
- General Dermatology
- Hidradenitis Suppurativa
- Melasma
- NP and PA
- Pediatric Dermatology
- Pigmentary Disorders
- Practice Management
- Precision Medicine and Biologics
- Prurigo Nodularis
- Psoriasis
- Psoriatic Arthritis
- Rare Disease
- Rosacea
- Skin Cancer
- Vitiligo
- Wound Care
Article
Harbingers of sedative risk
Author(s):
Chicago - Cosmetic surgeons need to freshen up their understanding of sedation and analgesia in order to competently supervise staff, according to P. Allan Klock, M.D., associate professor of anesthesia and critical care at the University of Chicago.
Newsletter
Like what you’re reading? Subscribe to Dermatology Times for weekly updates on therapies, innovations, and real-world practice tips.
Related Videos
Future Directions for IL-17 Inhibitors in Psoriasis and Psoriatic Arthritis Care
Future Perspectives: Can Innovative Topical Therapies Like Ruxolitinib Reduce Systemic Treatment Dependency in Pediatric AD?
Treatment Escalation and De-escalation Strategies in Pediatric AD: Positioning Ruxolitinib Cream in Clinical Decision-Making
Benefits of Nonsteroidal Topical JAK Inhibitors for Moderate Pediatric Atopic Dermatitis
Identifying and Addressing Critical Gaps in Pediatric Atopic Dermatitis Treatment with Ruxolitinib Cream
Utility of Head-to-Head Studies in Atopic Dermatitis and Future Research Directions
Utility of Head-to-Head Studies in Psoriasis Management
Things to Consider With Treatment Sequencing for Pediatric Atopic Dermatitis
Larry Eichenfield, MD: Icotrokinra Demonstrates Promising Results for Adolescents With Moderate to Severe Plaque Psoriasis
Case 2: Poorly Managed GPP Flares and Effisayil 2 Trial Results
Related Content
